Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.D., Duke University School of Medicine 1973
• Research
• 

  Selected Grants

  • Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) awarded by Merck 2017 - 2021
  • A multinational, phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of enzalutamide in pat awarded by Medivation, Inc. 2014 - 2019
  • A randomized phase 3 study comparing cabazitaxel/prednisone in combination with Custirsen (OGX-011) to cabazitaxel/predn awarded by OncoGenex 2014 - 2019
  • A randomized, open-label, phase 2 study of sipuleucel-t with concurrent versus swquential administration of enzalutamide awarded by Dendreon Corporation 2014 - 2019
  • An open label, phase 1/2 safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive awarded by Aragon Pharmaceuticals, Inc 2014 - 2017
  • A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics awarded by Innocrin Pharmaceutical, Inc. 2014 - 2017

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.